Using Convergent Mixed Methods to Evaluate Treatment Risks and Benefits in Rare Disease: An Example From a Phase Ii Registration Trial in Metastatic Merkel Cell Carcinoma

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.1991
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Treatment–subgroup Interaction: An Example From a Published, Phase II Clinical Trial

Contemporary Clinical Trials
MedicinePharmacology
2009English

Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Urology
Urology
2008English

A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Updated Efficacy of Avelumab in Patients With Previously Treated Metastatic Merkel Cell Carcinoma After ≥1 Year of Follow-Up: JAVELIN Merkel 200, a Phase 2 Clinical Trial

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Recombinant Human Interleukin 6 in Metastatic Renal Cell Cancer: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
1996English

Radiotherapy for Metastatic Merkel Cell Carcinoma: A Review of the Literature

Journal of Skin Cancer
DermatologyOncology
2012English

Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

JAMA Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy